WORCESTER, Mass., March 11, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that canisters of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, have been labeled and packaged for Phase III clinical trial sites in the United States, Canada and Ukraine. Both placebo and active canisters are ready to be shipped to the clinical sites which will permit the initiation of the pivotal study. Clinical supplies of canisters for the balance of the sites are scheduled to be labeled and packaged in the next 45 days.
